Hepatocellular carcinoma: An update

Ultrastructural Pathology

Volumn 25, Issue 6, 2001, Pages 497-516

  Dominguez Malagon H ^a   Gaytan Graham, S ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; CD34 ANTIGEN; CYTOKERATIN; PROTEIN P53; RETICULIN; VIRUS DNA;

ALCOHOL CONSUMPTION; BILE DUCT CARCINOMA; CANCER INCIDENCE; CARCINOGENICITY; CELL PROLIFERATION; CELL ULTRASTRUCTURE; CODON; CYTOLOGY; DISEASE ASSOCIATION; ENDEMIC DISEASE; GENE ACTIVATION; HEMOCHROMATOSIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MICROVILLUS; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

CARCINOMA, HEPATOCELLULAR; CYTOPLASM; DIAGNOSIS, DIFFERENTIAL; FOCAL NODULAR HYPERPLASIA; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; ONCOGENES;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 0035652140     PISSN: 01913123     EISSN: None     Source Type: Journal    
DOI: 10.1080/019131201753343539     Document Type: Review

References (245)

1. Epidemiology of hepatocellular carcinoma
2. Familial clustering of asymptomatic primary liver cancer
3. Hepatocellular carcinoma in rural southern African blacks
4. Risk factors in development of hepatocellular carcinoma in cirrhosis: Prospective study of 613 patients
5. A serologic follow up of the 1942 epidemic of post-vaccinal hepatitis in the United States Army
6. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma
7. Hepatitis C virus: The major causative agent of viral non-A, non-B hepatitis
8. Pathogenesis of hepatocellular carcinoma: A review from the viewpoint of molecular analysis
9. Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma
10. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma: Epidemiologic considerations
11. Hepatocellular carcinoma occurring in nonfibrotic liver: Epidemiologic and histopathologic analysis of 80 French cases
12. Isozyme profiles of oval cells, parenchymal cells and biliary cells isolated by centrifugal elutriation from normal and preneoplastic livers
13. Production of hepatocellular carcinoma by oval cells: Cell cycle expression of c-myc and p53 at different stages of oval cell transformation
14. In vivo differentiation of rat liver cell into hepatocytes
15. In situ hybridization studies on expression of albumin and alphafetoprotein during the early stage of neoplastic transformation in rat liver
16. A precursor-product relationship exists between oval cells and hepatocytes in rat liver
17. An evaluation of cellular lineages in the pathogenesis of experimental hepatocellular carcinoma
18. Early histological and functional alterations of ethionine liver carcinogenesis in rats fed a choline-deficient diet
19. Intestinal metaplasia as a common option of oval cells in relation to cholangiofibrosis in liver of rats exposed to 2-acetyl-aminofluorene
20. Oval cell proliferation and the origin of small hepatocytes in liver injury induced by D-galactosamine
21. Cell lineages and differentiation programs in epidermal, urothelial and hepatic tissues and their neoplasms
22. Cellular biochemistry of the stepwise development of cancer with chemicals
23. Hepatic stem cells
24. The liver as a stem cell and lineage system
25. Is there a liver stem cell?
26. Hepatocyte differentiation and liver progenitor cells
27. Oval cells and liver carcinogenesis: An analysis of cell lineages in hepatic tumors using oncogene transfection techniques
28. Origin and fate of oval cells in dipin-induced hepatocarcinogenesis in the mouse
29. Differential cytokeratin and alpha-fetoprotein expression in morphologically distinct epithelial cells emerging at the early stage of rat hepatocarcinogenesis
30. An antigen portrait of the liver during carcinogenesis
31. Cell biology of hepatocarcinogenesis
32. Expression of hepatocyte growth factor and c-met genes during hepatic differentiation and liver development in the rat
33. Expression of transforming growth factor-alpha in regenerating liver and during hepatic differentiation
34. Investigation of several genes related to development of hepatocarcinogenesis in rats
35. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis
36. Increased levels of multiplication-stimulating activity, an insulin-like growth factor in fetal rat serum
37. Carcinogenesis of primary liver malignancies
38. Proliferation, apoptosis and induction of hepatic transcription factors are characteristic of the early response of biliary epithelial (oval) cells to chemical carcinogens
39. In vivo infusion of growth factors enhances the mitogenic response of rat hepatic ductal (oval) cells after administration of 2-acetylaminofluorene
40. C-myc-induced apoptosis in fibroblasts is inhibited by specific cytokines
41. Suppression of apoptosis allows differentiation and development of a multipotent hemopoietic cell line in the absence of added growth factors
42. Cell death and control of cell survival in the oligodendrocyte lineage
43. Induction of apoptosis in fibroblasts by c-myc protein
44. Effects of c-myc expression on cell cycle progression
45. Cellular distribution of c-myc transcripts during chemical hepatocarcinogenesis in rats
46. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy
47. The role of the stages of initiation and promotion in phenotypic diversity during hepatocarcinogenesis in the rat
48. Models of hepatocarcinogenesis in the rat-contrasts and comparisons
49. Hepatocellular carcinoma: Recent progress
50. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver
51. Persistance of resistant putative preneoplastic hepatocytes induced by N-nitrosodiethylamine or N-methyl-N-nitrosourea
52. The phenotypic stability of altered hepatic foci: Effects of withdrawal and subsequent readministration of phenobarbital
53. Studies in liver tumor promotion in the rat by orotic acid: Dose and minimum exposure time required for dietary orotic acid to promote hepatocarcinogenesis
54. Quantitative evaluation of the promotion by 2,3,7,8-tetrachlorodibenzo-p-dioxin of hepatocarcinogenesis from diethylnitrosamine
55. Rat liver foci bioassay
56. Quantitative relationship between initiation of hepatocarcinogenesis and induction of altered cell islands
57. Multiplicity of transforming growth factors in human malignant effussions
58. Some emerging general principles in the pathogenesis of hepatocellular carcinoma
59. Biochemical markers associated with the stages of promotion and progression during hepatocarcinogenesis in the rat
60. The molecular biology of carcinogenesis
61. The multistep nature of cancer
62. Mutational hotspot in the p53 gene in human hepatocellular carcinomas
63. Hepatocarcinogenesis: Hepatitis viruses and altered tumor suppressor gene function
64. Progression of colorectal cancer associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer
65. Reactivity of monoclonal antibodies to oncoproteins with normal rat liver, carcinogen-induced tumors and premalignant liver lesions
66. Oncogene expression in rat hepatomas and during hepatocarcinogenesis
67. Expression of H-ras and c-myc protooncogenes in isolated gamma-glutamyl trenspeptidase-positive rat hepatocytes and in hepatocellular carcinomas induced by diethylnitrosamine
68. Activated c-raf gene in a rat hepatocellular carcinoma induced by 2-amino-3-methylimidazol (4,5-f)quinoline
69. Mutational analysis of the H-ras oncogene in spontaneous C57BL/6 and C3H/He mouse liver tumors and tumors induced with genotoxic and nongenotoxic hepatocarcinogens
70. Detection of a cellular oncogene in spontaneous liver tumors of B6C3F1 mice
71. Activated oncogenes in B6C3F1 mouse liver tumors: Implications for risk assessment
72. Detection and identification of activated oncogenes in spontaneously occurring benign and malignant hepatocellular tumors of B6C3F1 mouse
73. C-myc gene amplification during hepatocarcinogenesis by a choline-devoid diet
74. Increased expression of c-jun gene during spontaneous hepatocarcinogenesis in LEC rats
75. Mutational activation of the c-Ha-ras gene in liver tumors of different rodent strains: Correlation with susceptibility to hepatocarcinogenesis
76. Incidence of mutations at codon 61 of the Ha-ras gene in liver tumors of mice genetically susceptible and resistant to hepatocarcinogenesis
77. Proto-oncogene activation in multistage murine hepatocarcinogenesis
78. Activation of ras oncogene in aflatoxin-induced rat liver carcinogenesis
79. Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B1-induced rat liver tumors
80. Activation of the c-Ki-ras oncogene in aflatoxin B1-induced hepatocellular carcinoma and adenoma in the rat detection by denaturing gradient gel electrophoresis
81. A lack of direct role of hepatitis B virus in the activation of ras and c-myc oncogenes in human hepatocellular carcinogenesis
82. Activated N-ras gene was found in human hepatoma tissue but only in a small fraction of the tumor cells
83. Low incidence of point mutation of c-ki-ras and N-ras oncogenes in human hepatocellular carcinoma
84. Analysis of ras gene mutations in human hepatic malignant tumors by polymerasa chain reaction and direct sequencing
85. Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma
86. C-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma
87. Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B virus transgenic mice
88. Tumor suppressor genes
89. Tumor suppressor genes
90. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers
91. p53 activates expression of HIC-1, a new candidate tumor suppressor gene on17p13.3
92. Altered methylation of ras oncogenes in benzidine-induced B6C3F1 mouse liver tumors
93. Hypomethylation of DNA: A possible nongenotoxic mechanism underlying the role of cell proliferation in carcinogenesis
94. The induction of liver cancer by dietary deficiency of choline and methionine without added carcinogens
95. Hepatocercinogenesis in rats fed with methyl-deficient, amino acid-defined diets
96. Differential sensitivity to loss of cytosine methyl groups within the hepatic p53 gene of folate/methyl deficient rats
97. Loss of somatic heterozygosity in hepatocellular carcinoma
98. Accumulation of allelic loss of arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma
99. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinoma
100. Tumor suppressor genes, growth factor genes and oncogenes in hepatitis B virus-associated hepatocellular carcinoma
101. Expression of the retinoblastoma gene product in human hepatocellular carcinoma
102. Evidence for the presence of two tumor-suppressor genes for hepatocellular carcinoma on chromosome 13q
103. Oncogenic forms of p53 inhibit p53-regulated gene expression
104. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma
105. P53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines
106. p53 expression in patients with cirrhosis with and without hepatocellular hepatocarcinoma
107. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
108. Molecular mechanism of hepatocarcinogenesis
109. P53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinoma from china
110. Aberrations of p53 gene in human hepatocellular carcinoma from China
111. p53 mutation in hepatocellular carcinoma after aflatoxinexposure
112. Pathogenesis of primary hepatocellular carcinoma
113. Mutation at codon 249 of p53 gene in a human hepatoblastoma
114. Association between aflatoxin content of food and hepatoma frequency in Uganda
115. Dietary aflatoxin and liver cancer - A population based study in Kenya
116. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei
117. Hepatitis B virus, aflatoxins and hepatocellular carcinoma in southern Guangxi, China
118. Aflatoxin exposure measured by urinary excretion of aflatoxin B1-guanine adduct and hepatitis B virus infection in areas with different liver cancer incidence in Kenya
119. Nuclear distribution of aflatoxin B1 and its interaction with histones in rat liver in vivo
120. Aflatoxin metabolism in humans: Detection of metabolites and nucleic acid adducts in urine by affinity chromatography
121. Mutational properties of the primary aflatoxin B1-DNA adduct
122. Molecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi Autonomous Region, People's Republic of China
123. Molecular dosimetry of aflatoxin DNA adducts in humans and experimental rat models
124. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma
125. Aflatoxin in liver cancer
126. An aflatoxin-associated, mutational hotstop in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico
127. P53 codon 249ser mutations in hepatocellular carcinoma patients with low aflatoxin exposure
128. p53 Mutations in human hepatocellular carcinoma from Germany
129. Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain
130. p53 gene mutation spectrum in hepatocellular carcinoma
131. p53 gene mutations and 17 p allelic deletions in hepatocellular carcinoma from Japan
132. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma
133. Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinoma
134. p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand
135. Codon 249 mutation of the p53 gene is a rare event in hepatocellular carcinomas from ethnic Chinese in Singapore
136. Hepatocellular carcinoma mutation
137. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens
138. Aflatoxin B1 induces the transversion of G>T in codon 249 of the p53 tumor suppressor gene in human hepatocytes
139. Aflatoxin and p53 abnormality in duck hepatocellular carcinoma
140. Allele-specific PCR amplification of p53 codon 249 GCT transversion in liver with hepatitis from aflatoxin B1-exposed and unexposed inddividuals
141. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma
142. Microdeletion asociated with the integration process of hepatitis B virus DNA
143. Chromosomal sites for hepatitis B virus integration in human hepatocellular carcinoma
144. Structural analysis of a hepatitis B virus genome integrated into chromosome 17p of a human hepatocellular carcinoma
145. Inversely repeating integrated hepatitis B virus DNA and cellular flanking sequences in the human hepatoma-derived cell line huSP
146. Hepatitis B virus integration in hepatocellular hepatocarcinoma DNA: Duplication of cellular flanking sequences at the integration site
147. A comparison of the molecular structure of integrated hepatitis B virus genomes in hepatocellular carcinoma cells and hepatocytes derived from the same patient
148. Tight clustering of human hepatitis B virus integration sites in hepatomas near a triple-stranded region
149. The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma
150. The core promoter of hepatitis B virus
151. Pathogenesis of hepatocellular carcinoma: A review from the viewpoint of molecular analysis
152. Hepatitis B virus integration site in hepatocellular carcinoma at chromosome 17;18 translocation
153. A chromosome 17:7 translocation is associated with a hepatitis B virus DNA integration in human hepatocellular carcinoma DNA
154. Deletion in chromosome 11p asssociated with a hepatitis B integration site in hepatocellular carcinoma
155. Chromosome aberrations and cancer
156. Co-amplification of integrated hepatitis B virus DNA and transforming gene hst-1 in a hepatocellular carcinoma
157. Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma
158. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma
159. Modification of cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma
160. Hepatitis B virus DNA integration and expression of an erb B-like gene in human hepatocellular carcinoma
161. Trans-activation of viral enhancers by the hepatitis B virus X protein
162. Transcriptional trans-activating function of hepatitis B virus
163. Hepatitis B virus X protein: Searching for a role in hepatocarcinogenesis
164. Hepatocellular carcinoma
165. Hepatitis B-X antigen and p53 in the development of hepatocellular carcinoma
166. The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis
167. Hepatitis viruses: Their role in human cancer
168. A trans-activating function encoded in the hepatitis B virus X gene is conserved in the integrated state
169. The pre 52/5 region of integrated hepatitis B virus DNA encodes a transcriptional transactivator
170. A transactivator function is generated by integration of Hepatitis B virus by pre52/5 sequences in human hepatocellular carcinomas DNA
171. Hepatitis C virus replication is associated with expression of transforming growth factor-alpha and insulin-like growth factor-II in cirrhotic livers
172. The role of hepatitis C virus in hepatocellular carcinoma
173. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma
174. Hepatitis C virus and hepatocellular carcinoma
175. HCV-asssociated liver cancer without cirrhosis
176. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
177. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients
178. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis: A case-control study
179. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma
180. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study
181. The significance of hepatitis B virus DNA detected in hepatocellular carcinoma of patients with hepatitis C
182. Characteristic difference of hepatocellular carcinoma between hepatitis B and C-viral infection in Japan
183. Natural history of inoperable hepatocellular carcinoma: Estrogen receptors status in the tumor is the strongest prognostic factor for survival
184. Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: Evaluation by CT during intraarterial injection of contrast medium
185. Tumors of the liven and intrahepatic bile ducts
186. Histological diagnosis of hepatocellular carcinoma
187. Terminology of nodular hepatocellular lesions
188. The usefulness of the reticulin stain in the differential diagnosis of liver nodules on fine-needle aspiration biopsy cell block preparations
189. Biopsy diagnosis of malignant versus benign liver "nodules": New helpful markers. An update
190. Neoangiogenesis and sinusoidal "capillarization in dysplastic nodules of the liver
191. The expression of cytokeratins 7,19, and 20 in primary and metastatic carcinomas of the liver
192. Adenocarcinomas metastatic to the liver: The value of cytokeratins 20 and 7 in the search for unknown primary tumors
193. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas
194. MOC-31 immunoreactivity in primary and metastatic carcinoma of the liver
195. MOC-31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinoma
196. Telomerase activity in cancer: A magic bullet of a mirage?
197. Surgical significance of telomerase activity in noncancerous liver tissue from patients with hepatocellular carcinoma
198. Quantitative evaluation of telomerase activity in small liver tumors: Analysis of ultrasonography-guided liver biopsy specimens
199. Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma
200. A re-evaluation of needle biopsy in the diagnosis of metastatic cancer of the liver
201. Value of heparinized fine-needle aspiration biopsy in liver malignancy
202. Fine needle-aspiration biopsy for diagnosis of malignant tumor in the liver
203. Ultrasonically-guided liver biopsy
204. Usefulness of diagnostic criteria for aspiration cytology of hepatocellular carcinoma
205. Cytodiagnosis of well differentiated hepatocellular carcinoma: Can indeterminate diagnoses be reduced?
206. Higado y páncreas
207. Cytodiagnosis of hepatocellular carcinoma in fine-needle aspirates of the liver: Its differentiation from reactive hepatocytes and metastatic adenocarcinoma
208. Cell features and patterns in fine-needle aspirates of hepatocellular carcinoma
209. Morphologic spectrum of hepatocellular carcinoma in fine needle aspiration biopsies
210. Cytologic aspects of fibrolamellar hepatocellular carcinoma in fine needle aspirates
211. A step-wise logistic regression analysis of hepatocellular carcinoma. An aspiration biopsy study
212. Immunocytochemical evaluation of liver fine-needle aspirations
213. Immunocytochemical localization of polyclonal carcinoembryonic antigen in hepatocellular carcinomas
214. Fine needle aspiration biopsy of hepatocellular carcinoma: Value of immunocytochemical and ultrastructural studies
215. Immunocytochemical staining of fine-needle aspiration biopsies of the liver as a diagnostic tool for hepatocellular carcinoma
216. PCEA canalicular immunostaining in fine-needle aspiration biopsy diagnosis of hepatocellular carcinoma
217. Polyclonal carcinoembryonic antigen staining in the cytologic differential diagnosis of primary and metastatic hepatic malignancies
218. Hepatocellular carcinoma versus carcinoma metastatic to the liver: Value of stains for carcinoembryonic antigen and napthylamidase in fine needle-aspiration biopsy material
219. Ultrastructure of liver cell and bile duct carcinomas
220. Hepatocellular carcinoma: Expression of basement membrane glycoproteins. An immunohistochemical approach
221. Hepatocellular carcinoma developed in noncirrhotic livers: Sinusoids in hepatocarcinoma
222. Alpha-smooth muscle actin-positive perisinusoidal stromal cells in human hepatocellular carcinoma
223. Ground glass cells in hepatocellular carcinoma
224. A black hepatocellular carcinoma with Dubin-Johnson-like pigment and Mallory bodies. A histochemical and ultrastructural study
225. Globular cytoplasmic inclusion bodies in a metastatic hepatocellular carcinoma
226. Ctologic, ultrastructural and immunologic features of intracytoplasmic hyaline bodies in fine needle aspirates of hepatocellular carcinoma
227. Histochemical and ultrastructural study of copper binding protein in hepatocellular carcinoma
228. A light microscopic and ultrastructural study of two cases of fibrolamelar hepatocellular carcinoma
229. Fibrolamellar carcinoma of the liver: A primary malignant oncocytic carcinoid?
230. Fibrolamellar liver carcinoma
231. Fibrolamellar carcinoma of the liver in a child: Ultrastructural and immunohistologic aspects
232. Hepatocellular carcinoma with carcinoid features
233. Endocrine liver tumor: Differential diagnosis from hepatocellular carcinoma
234. Primary neuroendocrine carcinoma of the liver
235. Melanin containing hepatoblastoma with endocrine differentiation: An immunohistochemical and ultrastructural study
236. Hepatocellular carcinoma with sarcomatous change: Clinicopathologic and immunocytochemical stuies of 14 autopsy cases
237. Undifferentiated (embryonal) sarcoma of the liver: Epithelial features as shown by immunocytochemical analysis and electron microscopic examination
238. A case of biliary cystadenocarcinoma with morphologic and histochemical features of hepatocytes
239. Solid adenosquamous carcinoma of the liver: A case report with review of the literature
240. Primary mucoepidermoid carcinoma of the liver: Case report
241. Hepatocarcinomas, cholangiocarcinomas and hepatoblastomas produced by chemically transformed cultured rat cell liver epithelial cells
242. The immunohistochemical profile of dysplastic foci in human liver: Correlation with putative progenitor cells
243. Expression of hepatitis B surface and core antigens and transforming growth factor-alpha in "oval cells" of the liver in patients with hepatocellular carcinoma
244. Hematopoietic stem cell markers are expressed by ductal plate and bile duct cells in developing human liver